The transforming growth factor-β superfamily of receptors

Cytokine and Growth Factor Reviews

Volumn 15, Issue 1, 2004, Pages 1-11

  De Caestecker, Mark ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Activin; BMP; GDF; Receptors; Signal transduction; Smads; TGF

Indexed keywords

ENDOGLIN; LIGAND; RECEPTOR SUBTYPE; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ENDOSOME; HUMAN; INTERNALIZATION; MAMMAL CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN INTERACTION; RECEPTOR INTRINSIC ACTIVITY; RECEPTOR UPREGULATION; SHORT SURVEY; SIGNAL TRANSDUCTION;

MAMMALIA;

EID: 1642473157     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2003.10.004     Document Type: Short Survey

References (160)

1. Pangas S.A., Woodruff T.K. Activin signal transduction pathways. Trends Endocrinol Metab. 11:2000;309-314.
2. Newfeld S.J., Wisotzkey R.G., Kumar S. Molecular evolution of a developmental pathway: phylogenetic analyses of transforming growth factor-beta family ligands. Genetics. 152:1999;783-795.
3. Kawabata M, Miyazono K. Skeletal growth factors. Philadelphia: Lippincott Williams & Wilkins; 2000.
4. Beck S., Le Good J.A., Guzman M., Ben Haim N., Roy K., Beermann F.et al. Extraembryonic proteases regulate Nodal signalling during gastrulation. Nat. Cell Biol. 4:2002;981-985.
5. Constam D.B., Robertson E.J. Regulation of bone morphogenetic protein activity by pro domains and proprotein convertases. J. Cell Biol. 144:1999;139-149.
6. Daopin S., Piez K.A., Ogawa Y., Davies D.R. Crystal structure of transforming growth factor-beta 2: an unusual fold for the superfamily. Science. 257:1992;369-373.
7. Mittl P.R., Priestle J.P., Cox D.A., McMaster G., Cerletti N., Grutter M.G. The crystal structure of TGF-beta 3 and comparison to TGF-beta 2: implications for receptor binding. Protein Sci. 5:1996;1261-1271.
8. Hinck A.P., Archer S.J., Qian S.W., Roberts A.B., Sporn M.B., Weatherbee J.A.et al. Transforming growth factor beta 1: three-dimensional structure in solution and comparison with the X-ray structure of transforming growth factor beta 2. Biochemistry. 35:1996;8517-8534.
9. Griffith D.L., Keck P.C., Sampath T.K., Rueger D.C., Carlson W.D. Three-dimensional structure of recombinant human osteogenic protein 1: structural paradigm for the transforming growth factor beta superfamily. Proc. Natl. Acad. Sci. USA. 93:1996;878-883.
10. Scheufler C., Sebald W., Hulsmeyer M. Crystal structure of human bone morphogenetic protein-2 at 2.7 Å resolution. J. Mol. Biol. 287:1999;103-115.
11. Thompson T.B., Woodruff T.K., Jardetzky T.S. Structures of an ActRIIB:activin A complex reveal a novel binding mode for TGF-beta ligand:receptor interactions. EMBO J. 22:2003;1555-1566.
12. McPherron A.C., Lee S.J. GDF-3 and GDF-9: two new members of the transforming growth factor-beta superfamily containing a novel pattern of cysteines. J. Biol. Chem. 268:1993;3444-3449.
13. Kirsch T., Sebald W., Dreyer M.K. Crystal structure of the BMP-2-BRIA ectodomain complex. Nat. Struct. Biol. 7:2000;492-496.
14. Hart P.J., Deep S., Taylor A.B., Shu Z., Hinck C.S., Hinck A.P. Crystal structure of the human TbetaR2 ectodomain - TGF-beta3 complex. Nat. Struct. Biol. 9:2002;203-208.
15. Munger J.S., Harpel J.G., Gleizes P.E., Mazzieri R., Nunes I., Rifkin D.B. Latent transforming growth factor-beta: structural features and mechanisms of activation. Kidney Int. 51:1997;1376-1382.
16. Balemans W., Van Hul W. Extracellular regulation of BMP signaling in vertebrates: a cocktail of modulators. Dev. Biol. 250:2002;231-250.
17. ten Dijke P., Ichijo H., Franzen P., Schulz P., Saras J., Toyoshima H.et al. Activin receptor-like kinases: a novel subclass of cell-surface receptors with predicted serine/threonine kinase activity. Oncogene. 8:1993;2879-2887.
18. ten Dijke P., Yamashita H., Ichijo H., Franzen P., Laiho M., Miyazono K.et al. Characterization of type I receptors for transforming growth factor-beta and activin. Science. 264:1994;101-104.
19. Zhao G.Q. Consequences of knocking out BMP signaling in the mouse. Genesis. 35:2003;43-56.
20. Whitman M., Mercola M. TGF-beta superfamily signaling and left-right asymmetry. Sci STKE. 2001:2001;RE1.
21. Chang H., Lau A.L., Matzuk M.M. Studying TGF-beta superfamily signaling by knockouts and knockins. Mol. Cell Endocrinol. 180:2001;39-46.
22. Massague J., Blain S.W., Lo R.S. TGFbeta signaling in growth control, cancer, and heritable disorders. Cell. 103:2000;295-309. [in process citation].
23. Risbridger G.P., Schmitt J.F., Robertson D.M. Activins and inhibins in endocrine and other tumors. Endocr. Rev. 22:2001;836-858.
24. Howe J.R., Bair J.L., Sayed M.G., Anderson M.E., Mitros F.A., Petersen G.M.et al. Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. Nat. Genet. 28:2001;184-187.
25. de Caestecker M.P., Meyrick B. Bone morphogenetic proteins, genetics and the pathophysiology of primary pulmonary hypertension. Respir. Res. 2:2001;193.
26. de Caestecker M.P., Piek E., Roberts A.B. Role of transforming growth factor-beta signaling in cancer. J. Natl. Cancer Inst. 92:2000;1388-1402. [in process citation].
27. Attisano L., Carcamo J., Ventura F., Weis F.M., Massague J., Wrana J.L. Identification of human activin and TGF beta type I receptors that form heteromeric kinase complexes with type II receptors. Cell. 75:1993;671-680.
28. Oh S.P., Seki T., Goss K.A., Imamura T., Yi Y., Donahoe P.K.et al. Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. Proc. Natl. Acad. Sci. USA. 97:2000;2626-2631.
29. Visser J.A., Olaso R., Verhoef-Post M., Kramer P., Themmen A.P., Ingraham H.A. The serine/threonine transmembrane receptor ALK2 mediates Mullerian inhibiting substance signaling. Mol Endocrinol. 15:2001;936-945.
30. Miettinen P.J., Ebner R., Lopez A.R., Derynck R. TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. J Cell Biol. 127:1994;2021-2036.
31. Macias-Silva M., Hoodless P.A., Tang S.J., Buchwald M., Wrana J.L. Specific activation of Smad1 signaling pathways by the BMP7 type I receptor, ALK2. J Biol Chem. 273:1998;25628-25636.
32. Yamashita H., ten Dijke P., Huylebroeck D., Sampath T.K., Andries M., Smith J.C.et al. Osteogenic protein-1 binds to activin type II receptors and induces certain activin-like effects. J Cell Biol. 130:1995;217-226.
33. Ebisawa T., Tada K., Kitajima I., Tojo K., Sampath T.K., Kawabata M.et al. Characterization of bone morphogenetic protein-6 signaling pathways in osteoblast differentiation. J Cell Sci. 112:1999;3519-3527.
34. ten Dijke P., Yamashita H., Sampath T.K., Reddi A.H., Estevez M., Riddle D.L.et al. Identification of type I receptors for osteogenic protein-1 and bone morphogenetic protein-4. J Biol Chem. 269:1994;16985-16988.
35. Erlacher L., McCartney J., Piek E., ten Dijke P., Yanagishita M., Oppermann H.et al. Cartilage-derived morphogenetic proteins and osteogenic protein-1 differentially regulate osteogenesis. J Bone Miner Res. 13:1998;383-392.
36. Moore R.K., Otsuka F., Shimasaki S. Molecular basis of bone morphogenetic protein-15 signaling in granulosa cells. J Biol Chem. 278:2003;304-310.
37. Gouedard L., Chen Y.G., Thevenet L., Racine C., Borie S., Lamarre I.et al. Engagement of bone morphogenetic protein type IB receptor and Smad1 signaling by anti-Mullerian hormone and its type II receptor. J Biol Chem. 275:2000;27973-27978.
38. Nishitoh H., Ichijo H., Kimura M., Matsumoto T., Makishima F., Yamaguchi A.et al. Identification of type I and type II serine/threonine kinase receptors for growth/differentiation factor-5. J Biol Chem. 271:1996;21345-21352.
39. Yeo C., Whitman M. Nodal signals to Smads through Cripto-dependent and Cripto-independent mechanisms. Mol Cell. 7:2001;949-957.
40. Oh S.P., Yeo C.Y., Lee Y., Schrewe H., Whitman M., Li E. Activin type IIA and IIB receptors mediate Gdf11 signaling in axial vertebral patterning. Genes Dev. 16:2002;2749-2754.
41. Lebrun J.J., Vale W.W. Activin and inhibin have antagonistic effects on ligand-dependent heteromerization of the type I and type II activin receptors and human erythroid differentiation. Mol Cell Biol. 17:1997;1682-1691.
42. Attisano L., Wrana J.L., Montalvo E., Massague J. Activation of signalling by the activin receptor complex. Mol Cell Biol. 16:1996;1066-1073.
43. Cheng S.K., Olale F., Bennett J.T., Brivanlou A.H., Schier A.F. EGF-CFC proteins are essential coreceptors for the TGF-beta signals Vg1 and GDF1. Genes Dev. 17:2003;31-36.
44. Wrana J.L., Attisano L., Carcamo J., Zentella A., Doody J., Laiho M.et al. TGF beta signals through a heteromeric protein kinase receptor complex. Cell. 71:1992;1003-1014.
45. Franzen P., ten Dijke P., Ichijo H., Yamashita H., Schulz P., Heldin C.H.et al. Cloning of a TGF beta type I receptor that forms a heteromeric complex with the TGF beta type II receptor. Cell. 75:1993;681-692.
46. Reissmann E., Jornvall H., Blokzijl A., Andersson O., Chang C., Minchiotti G.et al. The orphan receptor ALK7 and the Activin receptor ALK4 mediate signaling by Nodal proteins during vertebrate development. Genes Dev. 15:2001;2010-2022.
47. Rosenzweig B.L., Imamura T., Okadome T., Cox G.N., Yamashita H., ten Dijke P.et al. Cloning and characterization of a human type II receptor for bone morphogenetic proteins. Proc Natl Acad Sci USA. 92:1995;7632-7636.
48. Liu F., Ventura F., Doody J., Massague J. Human type II receptor for bone morphogenic proteins (BMPs): extension of the two-kinase receptor model to the BMPs. Mol Cell Biol. 15:1995;3479-3486.
49. Wiater E., Vale W. Inhibin is an antagonist of bone morphogenetic protein signaling. J Biol Chem. 278:2003;7934-7941.
50. Lee S.J., McPherron A.C. Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci USA. 98:2001;9306-9311.
51. Chapman S.C., Bernard D.J., Jelen J., Woodruff T.K. Properties of inhibin binding to betaglycan, InhBP/p120 and the activin type II receptors. Mol Cell Endocrinol. 196:2002;79-93.
52. Wrana J.L., Attisano L., Wieser R., Ventura F., Massague J. Mechanism of activation of the TGF-beta receptor. Nature. 370:1994;341-347.
53. Willis S.A., Zimmerman C.M., Li L.I., Mathews L.S. Formation and activation by phosphorylation of activin receptor complexes. Mol Endocrinol. 10:1996;367-379.
54. Koenig B.B., Cook J.S., Wolsing D.H., Ting J., Tiesman J.P., Correa P.E.et al. Characterization and cloning of a receptor for BMP-2 and BMP-4 from NIH 3T3 cells. Mol Cell Biol. 14:1994;5961-5974.
55. Greenwald J., Groppe J., Gray P., Wiater E., Kwiatkowski W., Vale W.et al. The BMP7/ActRII extracellular domain complex provides new insights into the cooperative nature of receptor assembly. Mol Cell. 11:2003;605-617.
56. Moussad E.E., Brigstock D.R. Connective tissue growth factor: what's in a name? Mol Genet Metab. 71:2000;276-292.
57. Abreu J.G., Ketpura N.I., Reversade B., De Robertis E.M. Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta. Nat Cell Biol. 4:2002;599-604.
58. Groppe J., Greenwald J., Wiater E., Rodriguez-Leon J., Economides A.N., Kwiatkowski W.et al. Structural basis of BMP signalling inhibition by the cystine knot protein Noggin. Nature. 420:2002;636-642.
59. Lux A., Attisano L., Marchuk D.A. Assignment of transforming growth factor beta1 and beta3 and a third new ligand to the type I receptor ALK-1. J Biol Chem. 274:1999;9984-9992.
60. Ebner R., Chen R.H., Lawler S., Zioncheck T., Derynck R. Determination of type I receptor specificity by the type II receptors for TGF-beta or activin. Science. 262:1993;900-902.
61. Nohe A., Hassel S., Ehrlich M., Neubauer F., Sebald W., Henis Y.I.et al. The mode of bone morphogenetic protein (BMP) receptor oligomerization determines different BMP-2 signaling pathways. J Biol Chem. 277:2002;5330-5338.
62. Wells R.G., Gilboa L., Sun Y., Liu X., Henis Y.I., Lodish H.F. Transforming growth factor-beta induces formation of a dithiothreitol-resistant type I/type II receptor complex in live cells. J Biol Chem. 274:1999;5716-5722.
63. Yamashita H., ten Dijke P., Franzen P., Miyazono K., Heldin C.H. Formation of hetero-oligomeric complexes of type I and type II receptors for transforming growth factor-beta. J Biol Chem. 269:1994;20172-20178.
64. Sampath T.K., Coughlin J.E., Whetstone R.M., Banach D., Corbett C., Ridge R.J.et al. Bovine osteogenic protein is composed of dimers of OP-1 and BMP-2A, two members of the transforming growth factor-beta superfamily. J Biol Chem. 265:1990;13198-13205.
65. Israel D.I., Nove J., Kerns K.M., Kaufman R.J., Rosen V., Cox K.A.et al. Heterodimeric bone morphogenetic proteins show enhanced activity in vitro and in vivo. Growth Factors. 13:1996;291-300.
66. Nishimatsu S., Thomsen G.H. Ventral mesoderm induction and patterning by bone morphogenetic protein heterodimers in Xenopus embryos. Mech Dev. 74:1998;75-88.
67. Lewis K.A., Gray P.C., Blount A.L., MacConell L.A., Wiater E., Bilezikjian L.M.et al. Betaglycan binds inhibin and can mediate functional antagonism of activin signalling. Nature. 404:2000;411-414.
68. Sakuma R., Ohnishi Yi Y., Meno C., Fujii H., Juan H., Takeuchi J.et al. Inhibition of Nodal signalling by Lefty mediated through interaction with common receptors and efficient diffusion. Genes Cells. 7:2002;401-412.
69. Piek E., Afrakhte M., Sampath K., van Zoelen E.J., Heldin C.H., ten Dijke P. Functional antagonism between activin and osteogenic protein-1 in human embryonal carcinoma cells. J Cell Physiol. 180:1999;141-149.
70. O'Grady P., Liu Q., Huang S.S., Huang J.S. Transforming growth factor beta (TGF-beta) type V receptor has a TGF-beta-stimulated serine/threonine- specific autophosphorylation activity. J Biol Chem. 267:1992;21033-21037.
71. Piek E., Franzen P., Heldin C.H., ten Dijke P. Characterization of a 60-kDa cell surface-associated transforming growth factor-beta binding protein that can interfere with transforming growth factor-beta receptor binding. J Cell Physiol. 173:1997;447-459.
72. Tam B.Y., Larouche D., Germain L., Hooper N.M., Philip A. Characterization of a 150 kDa accessory receptor for TGF-beta 1 on keratinocytes: direct evidence for a GPI anchor and ligand binding of the released form. J Cell Biochem. 83:2001;494-507.
73. Lopez-Casillas F., Cheifetz S., Doody J., Andres J.L., Lane W.S., Massague J. Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-beta receptor system. Cell. 67:1991;785-795.
74. Lopez-Casillas F., Wrana J.L., Massague J. Betaglycan presents ligand to the TGF beta signaling receptor. Cell. 73:1993;1435-1444.
75. Sankar S., Mahooti-Brooks N., Centrella M., McCarthy T.L., Madri J.A. Expression of transforming growth factor type III receptor in vascular endothelial cells increases their responsiveness to transforming growth factor beta 2. J Biol Chem. 270:1995;13567-13572.
76. Blobe G.C., Schiemann W.P., Pepin M.C., Beauchemin M., Moustakas A., Lodish H.F.et al. Functional roles for the cytoplasmic domain of the type III transforming growth factor beta receptor in regulating transforming growth factor beta signaling. J Biol Chem. 276:2001;24627-24637.
77. Blobe G.C., Liu X., Fang S.J., How T., Lodish H.F. A novel mechanism for regulating transforming growth factor beta (TGF-beta) signaling. Functional modulation of type III TGF-beta receptor expression through interaction with the PDZ domain protein, GIPC. J Biol Chem. 276:2001;39608-39617.
78. Cheifetz S., Bellon T., Cales C., Vera S., Bernabeu C., Massague J.et al. Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem. 267:1992;19027-19030.
79. Barbara N.P., Wrana J.L., Letarte M. Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily. J Biol Chem. 274:1999;584-594.
80. St-Jacques S., Forte M., Lye S.J., Letarte M. Localization of endoglin, a transforming growth factor-beta binding protein, and of CD44 and integrins in placenta during the first trimester of pregnancy. Biol Reprod. 51:1994;405-413.
81. Pierelli L., Bonanno G., Rutella S., Marone M., Scambia G., Leone G. CD105 (endoglin) expression on hematopoietic stem/progenitor cells. Leuk Lymphoma. 42:2001;1195-1206.
82. Qu R., Silver M.M., Letarte M. Distribution of endoglin in early human development reveals high levels on endocardial cushion tissue mesenchyme during valve formation. Cell Tissue Res. 292:1998;333-343.
83. Letamendia A., Lastres P., Botella L.M., Raab U., Langa C., Velasco B.et al. Role of endoglin in cellular responses to transforming growth factor-beta. A comparative study with betaglycan. J Biol Chem. 273:1998;33011-33019.
84. Wong S.H., Hamel L., Chevalier S., Philip A. Endoglin expression on human microvascular endothelial cells association with betaglycan and formation of higher order complexes with TGF-beta signalling receptors. Eur J Biochem. 267:2000;5550-5560.
85. Shen M.M., Schier A.F. The EGF-CFC gene family in vertebrate development. Trends Genet. 16:2000;303-309.
86. Gray P.C., Harrison C.A., Vale W. Cripto forms a complex with activin and type II activin receptors and can block activin signaling. Proc Natl Acad Sci USA. 100:2003;5193-5198.
87. Degen W.G., Weterman M.A., van Groningen J.J., Cornelissen I.M., Lemmers J.P., Agterbos M.A.et al. Expression of nma, a novel gene, inversely correlates with the metastatic potential of human melanoma cell lines and xenografts. Int J Cancer. 65:1996;460-465.
88. Tsang M., Kim R., de Caestecker M.P., Kudoh T., Roberts A.B., Dawid I.B. Zebrafish NMA is involved in TGFbeta family signaling. Genesis. 28:2000;47-57.
89. Onichtchouk D., Chen Y.G., Dosch R., Gawantka V., Delius H., Massague J.et al. Silencing of TGF-beta signalling by the pseudoreceptor BAMBI. Nature. 401:1999;480-485.
90. Johnson L.N., Noble M.E., Owen D.J. Active and inactive protein kinases: structural basis for regulation. Cell. 85:1996;149-158.
91. Huse M., Chen Y.G., Massague J., Kuriyan J. Crystal structure of the cytoplasmic domain of the type I TGF beta receptor in complex with FKBP12. Cell. 96:1999;425-436.
92. Huse M., Muir T.W., Xu L., Chen Y.G., Kuriyan J., Massague J. The TGF beta receptor activation process: an inhibitor- to substrate-binding switch. Mol Cell. 8:2001;671-682.
93. Wang T., Li B.Y., Danielson P.D., Shah P.C., Rockwell S., Lechleider R.J.et al. The immunophilin FKBP12 functions as a common inhibitor of the TGF beta family type I receptors. Cell. 86:1996;435-444.
94. Liu X., Nagarajan R.P., Vale W., Chen Y. Phosphorylation regulation of the interaction between Smad7 and activin type I receptor. FEBS Lett. 519:2002;93-98.
95. Ulloa L., Doody J., Massague J. Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. Nature. 397:1999;710-713.
96. Imamura T., Takase M., Nishihara A., Oeda E., Hanai J., Kawabata M.et al. Smad6 inhibits signalling by the TGF-beta superfamily. Nature. 389:1997;622-626.
97. Nakao A., Afrakhte M., Moren A., Nakayama T., Christian J.L., Heuchel R.et al. Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature. 389:1997;631-635.
98. Bitzer M., von Gersdorff G., Liang D., Dominguez-Rosales A., Beg A.A., Rojkind M.et al. A mechanism of suppression of TGF-beta/SMAD signaling by NF-kappa B/RelA. Genes Dev. 14:2000;187-197.
99. Topper J.N., Cai J., Qiu Y., Anderson K.R., Xu Y.Y., Deeds J.D.et al. Vascular MADs: two novel MAD-related genes selectively inducible by flow in human vascular endothelium. Proc Natl Acad Sci USA. 94:1997;9314-9319.
100. Attisano L., Wrana andJ.L. Smads as transcriptional co-modulators. Curr Opin Cell Biol. 12:2000;235-243.
101. Massague J., Wotton D. Transcriptional control by the TGF-beta/Smad signaling system. EMBO J. 19:2000;1745-1754.
102. Miyazono K., Kusanagi K., Inoue H. Divergence and convergence of TGF-beta/BMP signaling. J Cell Physiol. 187:2001;265-276.
103. Tsukazaki T., Chiang T.A., Davison A.F., Attisano L., Wrana J.L. SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor. Cell. 95:1998;779-791.
104. Hocevar B.A., Smine A., Xu X.X., Howe P.H. The adaptor molecule disabled-2 links the transforming growth factor beta receptors to the Smad pathway. EMBO J. 20:2001;2789-2801.
105. Felici A., Wurthner J.U., Parks W.T., Giam L.R., Reiss M., Karpova T.S. et al. TLP, a novel modulator of TGF-beta signaling, has opposite effects on Smad2- and Smad3-dependent signaling. EMBO J. 22:2003;4465-4477.
106. Wurthner J.U., Frank D.B., Felici A., Green H.M., Cao Z., Schneider M.D.et al. Transforming growth factor-beta receptor-associated protein 1 is a Smad4 chaperone. J Biol Chem. 276:2001;19495-19502.
107. Raju G.P., Dimova N., Klein P.S., Huang H.C. SANE, a novel LEM domain protein, regulates bone morphogenetic protein signaling through interaction with Smad1. J Biol Chem. 278:2003;428-437.
108. Miura S., Takeshita T., Asao H., Kimura Y., Murata K., Sasaki Y.et al. Hgs (Hrs), a FYVE domain protein, is involved in Smad signaling through cooperation with SARA. Mol Cell Biol. 20:2000;9346-9355.
109. Furuhashi M., Yagi K., Yamamoto H., Furukawa Y., Shimada S., Nakamura Y.et al. Axin facilitates Smad3 activation in the transforming growth factor beta signaling pathway. Mol Cell Biol. 21:2001;5132-5141.
110. Tang Y., Katuri V., Dillner A., Mishra B., Deng C.X., Mishra L. Disruption of transforming growth factor-beta signaling in ELF beta-spectrin-deficient mice. Science. 299:2003;574-577.
111. Wu G., Chen Y.G., Ozdamar B., Gyuricza C.A., Chong P.A., Wrana J.L.et al. Structural basis of Smad2 recognition by the Smad anchor for receptor activation. Science. 287:2000;92-97.
112. Chen Y.G., Massague J. Smad1 recognition and activation by the ALK1 group of transforming growth factor-beta family receptors. J Biol Chem. 274:1999;3672-3677.
113. Chen Y.G., Hata A., Lo R.S., Wotton D., Shi Y., Pavletich N.et al. Determinants of specificity in TGF-beta signal transduction. Genes Dev. 12:1998;2144-2152.
114. Goumans M.J., Valdimarsdottir G., Itoh S., Rosendahl A., Sideras P., ten Dijke P. Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J. 21:2002;1743-1753.
115. Ota T., Fujii M., Sugizaki T., Ishii M., Miyazawa K., Aburatani H.et al. Targets of transcriptional regulation by two distinct type I receptors for transforming growth factor-beta in human umbilical vein endothelial cells. J Cell Physiol. 193:2002;299-318.
116. Ceresa B.P., Schmid S.L. Regulation of signal transduction by endocytosis. Curr Opin Cell Biol. 12:2000;204-210.
117. Di Guglielmo G.M., Le Roy C., Goodfellow A.F., Wrana J.L. Distinct endocytic pathways regulate TGF-beta receptor signalling and turnover. Nat Cell Biol. 5:2003;410-421.
118. Penheiter S.G., Mitchell H., Garamszegi N., Edens M., Dore J.J. Jr., Leof E.B. Internalization-dependent and -independent requirements for transforming growth factor beta receptor signaling via the Smad pathway. Mol Cell Biol. 22:2002;4750-4759.
119. Razani B., Zhang X.L., Bitzer M., von Gersdorff G., Bottinger E.P., Lisanti M.P. Caveolin-1 regulates transforming growth factor (TGF)-beta/SMAD signaling through an interaction with the TGF-beta type I receptor. J Biol Chem. 276:2001;6727-6738.
120. Kavsak P., Rasmussen R.K., Causing C.G., Bonni S., Zhu H., Thomsen G.H. et al. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. Mol Cell. 6:2000;1365-1375.
121. Parks W.T., Frank D.B., Huff C., Renfrew Haft C., Martin J., Meng X.et al. Sorting nexin 6, a novel SNX, interacts with the transforming growth factor-beta family of receptor serine-threonine kinases. J Biol Chem. 276:2001;19332-19339.
122. Suzuki C., Murakami G., Fukuchi M., Shimanuki T., Shikauchi Y., Imamura T.et al. Smurf1 regulates the inhibitory activity of Smad7 by targeting Smad7 to the plasma membrane. J Biol Chem. 277:2002;39919-39925.
123. Ebisawa T., Fukuchi M., Murakami G., Chiba T., Tanaka K., Imamura T.et al. Smurf1 interacts with transforming growth factor-beta type I receptor through Smad7 and induces receptor degradation. J Biol Chem. 276:2001;12477-12480.
124. Frey R.S., Mulder K.M. TGFbeta regulation of mitogen-activated protein kinases in human breast cancer cells. Cancer Lett. 117:1997;41-50.
125. Watanabe H., de Caestecker M.P., Yamada Y. Transcriptional cross-talk between Smad, ERK1/2, and p38 mitogen-activated protein kinase pathways regulates transforming growth factor-beta-induced aggrecan gene expression in chondrogenic ATDC5 cells. J Biol Chem. 276:2001;14466-14473.
126. Hayashida T., de caestecker M., Schnaper H.W. Cross-talk between ERK MAP kinase and Smad signaling pathways enhances TGF-beta-dependent responses in human mesangial cells. FASEB J. 17:2003;1576-1578.
127. Hartsough M.T., Mulder K.M. Transforming growth factor beta activation of p44mapk in proliferating cultures of epithelial cells. J Biol Chem. 270:1995;7117-7124.
128. Engel M.E., McDonnell M.A., Law B.K., Moses H.L. Interdependent SMAD and JNK signaling in transforming growth factor-beta-mediated transcription. J Biol Chem. 274:1999;37413-37420.
129. Hocevar B.A., Brown T.L., Howe P.H. TGF-beta induces fibronectin synthesis through a c-Jun N-terminal kinase-dependent, Smad4-independent pathway. EMBO J. 18:1999;1345-1356.
130. Atfi A., Djelloul S., Chastre E., Davis R., Gespach C. Evidence for a role of Rho-like GTPases and stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) in transforming growth factor beta-mediated signaling. J Biol Chem. 272:1997;1429-1432.
131. Dai C., Yang J., Liu Y. Transforming growth factor-beta1 potentiates renal tubular epithelial cell death by a mechanism independent of Smad signaling. J Biol Chem. 278:2003;12537-12545.
132. Yu L., Hebert M.C., Zhang Y.E. TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses. EMBO J. 21:2002;3749-3759.
133. Bakin A.V., Tomlinson A.K., Bhowmick N.A., Moses H.L., Arteaga C.L. Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J Biol Chem. 275:2000;36803-36810.
134. Krymskaya V.P., Hoffman R., Eszterhas A., Ciocca V., Panettieri R.A. Jr. TGF-beta 1 modulates EGF-stimulated phosphatidylinositol 3-kinase activity in human airway smooth muscle cells. Am J Physiol. 273:1997;L1220-1227.
135. Ghosh-Choudhury N., Abboud S.L., Nishimura R., Celeste A., Mahimainathan L., Choudhury G.G. Requirement of BMP-2-induced phosphatidylinositol 3-kinase and Akt serine/threonine kinase in osteoblast differentiation and Smad- dependent BMP-2 gene transcription. J Biol Chem. 277:2002;33361-33368.
136. Runyan C.E., Schnaper H.W., Poncelet A.C. Smad3 and PKC{delta} mediate TGF-{beta}1-induced collagen I expression in human mesangial cells. Am J Physiol Renal Physiol. 285:2003;F413-F422.
137. Hay E., Lemonnier J., Fromigue O., Marie P.J. Bone morphogenetic protein-2 promotes osteoblast apoptosis through a Smad-independent, protein kinase C-dependent signaling pathway. J Biol Chem. 276:2001;29028-29036.
138. Vinals F., Lopez-Rovira T., Rosa J.L., Ventura F. Inhibition of PI3K/p70 S6K and p38 MAPK cascades increases osteoblastic differentiation induced by BMP-2. FEBS Lett. 510:2002;99-104.
139. Petritsch C., Beug H., Balmain A., Oft M. TGF-beta inhibits p70 S6 kinase via protein phosphatase 2A to induce G(1) arrest. Genes Dev. 14:2000;3093-3101.
140. Lee K.S., Hong S.H., Bae S.C. Both the Smad and p38 MAPK pathways play a crucial role in Runx2 expression following induction by transforming growth factor-beta and bone morphogenetic protein. Oncogene. 21:2002;7156-7163.
141. Perlman R., Schiemann W.P., Brooks M.W., Lodish H.F., Weinberg R.A. TGF-beta-induced apoptosis is mediated by the adapter protein Daxx that facilitates JNK activation. Nat Cell Biol. 3:2001;708-714.
142. Itoh S., Thorikay M., Kowanetz M., Moustakas A., Itoh F., Heldin C.H.et al. Elucidation of Smad requirement in transforming growth factor-beta type I receptor-induced responses. J Biol Chem. 278:2003;3751-3761.
143. Jono H., Xu H., Kai H., Lim D.J., Kim Y.S., Feng X.H.et al. Transforming growth factor-beta-Smad signaling pathway negatively regulates nontypeable Haemophilus influenzae-induced MUC5AC mucin transcription via mitogen-activated protein kinase (MAPK) phosphatase-1-dependent inhibition of p38 MAPK. J Biol Chem. 278:2003;27811-27819.
144. Wang W., Zhou G., Hu M.C., Yao Z., Tan T.H. Activation of the hematopoietic progenitor kinase-1 (HPK1)-dependent, stress-activated c-Jun N-terminal kinase (JNK) pathway by transforming growth factor beta (TGF-beta)-activated kinase (TAK1), a kinase mediator of TGF beta signal transduction. J Biol Chem. 272:1997;22771-22775.
145. Zhou G., Lee S.C., Yao Z., Tan T.H. Hematopoietic progenitor kinase 1 is a component of transforming growth factor beta-induced c-Jun N-terminal kinase signaling cascade. J Biol Chem. 274:1999;13133-13138.
146. Hartsough M.T., Frey R.S., Zipfel P.A., Buard A., Cook S.J., McCormick F., Mulder K.M. Altered transforming growth factor signaling in epithelial cells when ras activation is blocked. J Biol Chem. 271:1996;22368-22375.
147. Hanafusa H., Ninomiya-Tsuji J., Masuyama N., Nishita M., Fujisawa J., Shibuya H.et al. Involvement of the p38 mitogen-activated protein kinase pathway in transforming growth factor-beta-induced gene expression. J Biol Chem. 274:1999;27161-27167.
148. Yamaguchi K., Nagai S., Ninomiya-Tsuji J., Nishita M., Tamai K., Irie K.et al. XIAP, a cellular member of the inhibitor of apoptosis protein family, links the receptors to TAB1-TAK1 in the BMP signaling pathway. EMBO J. 18:1999;179-187.
149. Birkey Reffey S., Wurthner J.U., Parks W.T., Roberts A.B., Duckett C.S. X-linked inhibitor of apoptosis protein functions as a cofactor in transforming growth factor-beta signaling. J Biol Chem. 276:2001;26542-26549.
150. Bhowmick N.A., Ghiassi M., Bakin A., Aakre M., Lundquist C.A., Engel M.E.et al. Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell. 12:2001;27-36.
151. Hubchak S.C., Runyan C.E., Kreisberg J.I., Schnaper H.W. Cytoskeletal rearrangement and signal transduction in TGF-beta1-stimulated mesangial cell collagen accumulation. J Am Soc Nephrol. 14:2003;1969-1980.
152. Riedy M.C., Brown M.C., Molloy C.J., Turner C.E. Activin A and TGF-beta stimulate phosphorylation of focal adhesion proteins and cytoskeletal reorganization in rat aortic smooth muscle cells. Exp Cell Res. 251:1999;194-202.
153. Foletta V.C., Lim M.A., Soosairaiah J., Kelly A.P., Stanley E.G., Shannon M., He W., Das S., Massague J., Bernard O. Direct signaling by the BMP type II receptor via the cytoskeletal regulator LIMK1. J Cell Biol. 162:2003;1089-1098.
154. Edlund S., Landstrom M., Heldin C.H., Aspenstrom P. Transforming growth factor-beta-induced mobilization of actin cytoskeleton requires signaling by small GTPases Cdc42 and RhoA. Mol Biol Cell. 13:2002;902-914.
155. Arber S., Barbayannis F.A., Hanser H., Schneider C., Stanyon C.A., Bernard O.et al. Regulation of actin dynamics through phosphorylation of cofilin by LIM-kinase. Nature. 393:1998;805-809.
156. Roovers K., Klein E.A., Castagnino P., Assoian R.K. Nuclear translocation of LIM kinase mediates Rho-Rho kinase regulation of cyclin D1 expression. Dev Cell. 5:2003;273-284.
157. Yakymovych I., Engstrom U., Grimsby S., Heldin C.H., Souchelnytskyi S. Inhibition of transforming growth factor-beta signaling by low molecular weight compounds interfering with ATP- or substrate-binding sites of the TGF beta type I receptor kinase. Biochemistry. 41:2002;11000-11007.
158. Inman G.J., Nicolas F.J., Callahan J.F., Harling J.D., Gaster L.M., Reith A.D.et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol. 62:2002;65-74.
159. Callahan J.F., Burgess J.L., Fornwald J.A., Gaster L.M., Harling J.D., Harrington F.P.et al. Identification of novel inhibitors of the transforming growth factor beta1 (TGF-beta1) type 1 receptor (ALK5). J Med Chem. 45:2002;999-1001.
160. Rebbapragada A., Benchabane H., Wrana J.L., Celeste A.J., Attisano L. Myostatin signals through a transforming growth factor beta-like signaling pathway to block adipogenesis. Mol Cell Biol. 23:2003;7230-7242.